Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Receivables (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Change in Receivables for 17 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 47.71% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $485000.0 through Dec 2025, up 106.56% year-over-year, with the annual reading at $485000.0 for FY2025, 106.56% up from the prior year.
  • Change in Receivables hit $16.5 million in Q4 2025 for Integra Lifesciences Holdings, up from -$22.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $31.5 million in Q4 2024 to a low of -$28.8 million in Q3 2024.
  • Historically, Change in Receivables has averaged $756700.0 across 5 years, with a median of $4.2 million in 2022.
  • Biggest YoY gain for Change in Receivables was 6784.68% in 2024; the steepest drop was 12734.82% in 2024.
  • Year by year, Change in Receivables stood at $10.2 million in 2021, then fell by 1.35% to $10.0 million in 2022, then crashed by 95.45% to $457000.0 in 2023, then soared by 6784.68% to $31.5 million in 2024, then tumbled by 47.71% to $16.5 million in 2025.
  • Business Quant data shows Change in Receivables for IART at $16.5 million in Q4 2025, -$22.5 million in Q3 2025, and $28.0 million in Q2 2025.